Antimicrobials
Cefoxitin

Cefoxitin

Low
N/A

Dosing

General Information

Administration

  • IM administration generally not recommended due to pain
  • Administer IV push over 3-5 minutes
  • Administer intermittent infusion over 10-60 minutes

Preparation

  • Reconstitute vials with SWFI, bacteriostatic water, NS or D5W
  • May be further diluted in NS, D5(1/4)NS, D5(1/2)NS, D5NS, D5W, D10W, LR, mannitol 5-10% or sodium bicarbonate 5%

Compatibility

  • D5W, LR, NS
  • Animal bite wounds
  • Nontuberculous mycobacterial disease
  • Pelvic inflammatory disease
  • Surgical prophylaxis

Tier 1 Protected Antimicrobial

  • Narrow spectrum, possible transition for discharge, IV to PO
  • Strategy: Total EBM duration set (inpatient and outpatient)
  • Prothrombin time
  • Renal function periodically when co-administered with other nephrotoxic drugs
  • Diarrhea
  • Anaphylaxis
  • Bone marrow depression
  • Eosinophilia
  • Myasthenia gravis exacerbation
  • Hypotension
  • Increased SCr and serum transaminases
  • Nephrotoxicity
  • Aminoglycosides: enhanced nephrotoxicity, monitor closely or avoid combination
  • Probenecid: increases cephalosporin concentrations
  • Vitamin K Antagonists: enhanced anticoagulation activity of warfarin

Average half-life: 41-59 minutes, prolonged with renal impairment

  • Neonates and infants (PNA 10-53 days): 1.4 hours

Bile penetration: Therapeutic

CSF penetration: Poor, even with inflamed meninges

Pleural penetration: Therapeutic

Urine penetration: Therapeutic, 85% of unchanged drug is excreted in urine